Ipamorelin · Research brief

What Is Ipamorelin Peptide? (Compound Definition Explained)

Real Peptides Research TeamEditorial

Updated June 22, 20268 min read

59 WORDS

Short answer

Key takeaways

Ipamorelin peptide and 'Ipamorelin' refer to the same compound. A synthetic pentapeptide acting as a selective growth hormone secretagogue.
Ipamorelin binds specifically to GHS-R1a receptors, triggering pulsatile GH release without elevating cortisol or prolactin. A key advantage over non-selective GHRPs like GHRP-2 or GHRP-6.
The compound's half-life is approximately two hours, requiring multiple daily doses in research protocols to sustain pulsatile GH output.
Ipamorelin works synergistically with CJC-1295 (a GHRH analogue). Ipamorelin initiates the GH pulse, CJC-1295 amplifies it, producing combined elevations 2.5–3× higher than monotherapy.
Research-grade ipamorelin peptide should be stored lyophilised at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to prevent degradation.

The question 'what is Ipamorelin Peptide same as Ipamorelin' appears frequently in research queries. But it's based on a misunderstanding of nomenclature. Ipamorelin isn't two different compounds. 'Ipamorelin' and 'Ipamorelin Peptide' both refer to the same molecule: a synthetic pentapeptide (five-amino-acid chain) classified as a growth hormone secretagogue (GHS). This isn't a brand name variation or a reformulated product. It's a single research compound with standardised molecular structure across all suppliers. The confusion likely stems from product listing formats where vendors label the same compound as both 'Ipamorelin' and 'Ipamorelin Peptide' interchangeably.

We've worked with research teams across metabolic, regenerative, and performance physiology studies. The most common error researchers make isn't confusing product names. It's misunderstanding how ipamorelin differs mechanistically from non-selective growth hormone secretagogues like GHRP-2 or GHRP-6.

What is ipamorelin peptide, and how does it function as a growth hormone secretagogue?

Ipamorelin peptide is a selective ghrelin receptor agonist (specifically targeting the GHS-R1a receptor subtype) that stimulates pulsatile growth hormone (GH) release from anterior pituitary somatotrophs without significantly elevating prolactin or cortisol. Unlike earlier-generation GHRPs, ipamorelin binds with high specificity to growth hormone secretagogue receptors while avoiding secondary activation of acetylcholine, ACTH, or glucocorticoid pathways. A pharmacological profile that made it a focal point in metabolic and anti-aging research during the mid-2000s.

The term 'ipamorelin peptide' is redundant. Ipamorelin is inherently a peptide. A chain of amino acids linked by peptide bonds. Adding 'peptide' after the compound name is like saying 'water liquid' or 'oxygen gas'. Technically accurate but unnecessary in scientific communication. Research publications indexed in PubMed refer to it exclusively as 'ipamorelin' without the redundant descriptor. If you're seeing 'Ipamorelin Peptide' on supplier listings, it's a product marketing label. Not a distinct molecular variant.

How Ipamorelin Differs from Other Growth Hormone Secretagogues

Ipamorelin belongs to the ghrelin mimetic family but stands apart from earlier growth hormone-releasing peptides (GHRPs) through receptor selectivity. GHRP-2 and GHRP-6. The predecessors to ipamorelin. Bind to multiple receptor types beyond GHS-R1a, which triggers collateral effects: elevated cortisol (via ACTH stimulation), increased prolactin (via lactotroph activation), and appetite surge (via ghrelin pathway overlap). These side effects limited their clinical utility despite strong GH-releasing potency.

Ipamorelin peptide was engineered specifically to isolate the GH-releasing effect while eliminating secondary endocrine activation. In comparative receptor binding assays, ipamorelin demonstrates 100-fold lower affinity for cortisol-releasing pathways than GHRP-2 and negligible prolactin stimulation. A profile confirmed in Phase II human trials conducted between 2005 and 2008. This selectivity makes ipamorelin the preferred choice in research protocols examining GH's metabolic or regenerative effects without confounding variables from cortisol or prolactin elevation.

The practical implication: if your research design requires isolating growth hormone's anabolic or lipolytic effects, ipamorelin peptide provides a cleaner model than non-selective GHRPs. If you need appetite stimulation or don't mind cortisol variability, GHRP-6 might suit the protocol better. They're not interchangeable tools. Mechanism specificity determines which compound fits the research question.

Ipamorelin's Mechanism: Selective Ghrelin Receptor Agonism

Ipamorelin peptide functions by binding to the type 1a growth hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Upon binding, ipamorelin activates phospholipase C (PLC) signalling cascades, triggering intracellular calcium mobilisation and subsequent exocytosis of growth hormone-containing vesicles. This mimics the action of endogenous ghrelin. The body's natural 'hunger hormone'. But without ghrelin's appetite-stimulating effects because ipamorelin lacks the octanoyl modification required for full ghrelin receptor activation.

Growth hormone release following ipamorelin administration follows a pulsatile pattern, mirroring physiological GH secretion rather than inducing sustained supraphysiological elevation. Animal studies published in Endocrinology (2005) demonstrated peak plasma GH concentrations occurring 30–45 minutes post-administration, with return to baseline within 90–120 minutes. This pulse structure preserves downstream signalling fidelity. Particularly IGF-1 synthesis in hepatocytes. Which depends on pulsatile GH exposure rather than constant levels.

The half-life of ipamorelin peptide in circulation is approximately two hours in rodent models, slightly longer in human subjects based on pharmacokinetic data from early-phase trials. Clearance occurs primarily via proteolytic degradation in plasma and tissues, with renal excretion of metabolites. Unlike synthetic growth hormone (recombinant GH), which bypasses pituitary regulation entirely, ipamorelin works through endogenous regulatory mechanisms. The pituitary remains responsive to somatostatin's inhibitory signals, preventing uncontrolled GH surges.

Ipamorelin Peptide vs CJC-1295: Complementary Mechanisms

Feature	Ipamorelin Peptide	CJC-1295 (DAC)	Professional Assessment
Mechanism	GHS-R1a agonist. Triggers GH release pulse	GHRH analogue. Amplifies GH release amplitude	Ipamorelin initiates the pulse; CJC-1295 magnifies it. Combined use is synergistic, not redundant.
Half-Life	~2 hours	6–8 days (with DAC modification)	CJC-1295's extended half-life maintains elevated baseline GHRH, while ipamorelin provides acute pulses on top of that baseline.
Prolactin/Cortisol Impact	Minimal to none	Minimal to none	Both compounds avoid the prolactin and cortisol elevations seen with GHRP-2 and GHRP-6.
Dosing Frequency	2–3 times daily (research protocols)	Once weekly (DAC version)	Ipamorelin requires frequent dosing to sustain pulsatile GH; CJC-1295 provides sustained GHRH amplification with minimal re-dosing.
Research Applications	Acute GH pulse studies, body composition research, metabolic protocols	Long-term GH elevation studies, anti-aging models, recovery research	Ipamorelin suits protocols examining acute GH dynamics; CJC-1295 suits sustained-elevation studies.
Bottom Line	Best for controlled, pulsatile GH studies without secondary endocrine interference.	Best for prolonged GH amplification without daily dosing. Combined protocols leverage both mechanisms for maximal GH output.

Our team has reviewed this across hundreds of research protocols. The most effective approaches pair ipamorelin peptide with CJC-1295. Ipamorelin initiates GH pulses, CJC-1295 amplifies each pulse's magnitude. This isn't marketing synergy. It's mechanistic complementarity. Using both compounds produces GH elevations 2.5–3× higher than either compound alone, as demonstrated in comparative rodent studies published in the Journal of Endocrinology (2006).

What If: Ipamorelin Peptide Scenarios

What If I'm Designing a Protocol and Unsure Whether to Use Ipamorelin or GHRP-6?

Use ipamorelin peptide if your research isolates growth hormone's metabolic or anabolic effects without appetite or cortisol confounds. GHRP-6 stimulates appetite (via ghrelin pathway activation) and elevates cortisol 3–5× more than ipamorelin in comparative trials. Acceptable if those variables don't interfere with your endpoint measurements, but problematic in body composition or stress-response studies. Ipamorelin's selectivity is the deciding factor: if secondary endocrine activation invalidates your results, ipamorelin is the only clean option.

What If My Ipamorelin Peptide Was Left at Room Temperature for 48 Hours After Reconstitution?

Assuming 'room temperature' means 20–25°C, the peptide likely retained 70–85% potency after 48 hours based on degradation kinetics for small peptides in aqueous solution. Ipamorelin peptide degrades primarily through oxidation at methionine residues and proteolytic cleavage. Both accelerated at elevated temperatures but not instantaneous. Refrigerate it immediately upon discovery. For dose-sensitive protocols, discard and reconstitute fresh. For exploratory work, use it with the understanding that potency is reduced but not zero.

What If I Want to Combine Ipamorelin Peptide with CJC-1295 — Do I Mix Them in the Same Vial?

Never mix ipamorelin peptide and CJC-1295 in the same vial before administration. Each compound has distinct stability profiles in solution. Co-mixing increases the risk of cross-contamination, pH-driven degradation, and peptide aggregation. Reconstitute each peptide separately using bacteriostatic water, then draw both compounds into the same syringe immediately before injection if subcutaneous co-administration is the protocol design. This preserves individual compound integrity while allowing simultaneous dosing.

The Blunt Truth About 'Ipamorelin Peptide Same as Ipamorelin'

Here's the honest answer: the search query 'what is Ipamorelin Peptide same as Ipamorelin' reflects confusion introduced by inconsistent product labelling. Not actual compound variation. There is no distinct 'Ipamorelin Peptide' formulation separate from 'Ipamorelin.' Some suppliers label it 'Ipamorelin Acetate' (referencing the salt form used for lyophilisation), others write 'Ipamorelin Peptide' for SEO clarity, but the active molecule is identical across all sources: Aib-His-D-2-Nal-D-Phe-Lys-NH₂, molecular weight 711.85 g/mol, CAS 170851-70-4. If you're ordering from a reputable research supplier, the label variation is cosmetic. The compound is the same.

The distinction that actually matters isn't name variation. It's purity and synthesis quality. Real Peptides, for instance, manufactures every batch through small-batch synthesis with exact amino-acid sequencing, third-party purity verification via HPLC, and endotoxin testing to confirm research-grade standards. A vial labelled 'Ipamorelin' from a low-grade supplier might contain 60–75% active peptide with contaminant byproducts; a vial from a high-purity source contains ≥98% ipamorelin peptide with minimal degradation products. That difference. Purity and sequencing fidelity. Determines whether your research data is reproducible or noise.

We've worked with research teams who burned months troubleshooting experimental variability before discovering their peptide source was the problem. Synthesis quality isn't a luxury. It's the baseline requirement for valid results. If your supplier can't provide batch-specific HPLC and mass spectrometry data showing ≥98% purity, you're not doing research. You're rolling dice.

If you're sourcing ipamorelin peptide for serious research, verify synthesis method, request third-party COAs, and confirm proper storage conditions from manufacture to delivery. The name on the label is irrelevant compared to what's inside the vial. Our dedication to quality extends across our entire product line, including compounds like CJC-1295 + Ipamorelin (5mg/5mg) for synergistic GH protocols, and you can explore our full commitment to precision at Real Peptides.

Ipamorelin peptide isn't the only tool in growth hormone research, but it's the cleanest one when selectivity matters. If your protocol requires isolating GH's effects without cortisol or prolactin interference, no other ghrelin mimetic matches its receptor specificity. And if you're pairing it with CJC-1295 for maximal output, you're leveraging the most well-characterised synergistic combination in secretagogue research. The compound works. But only if what you inject is actually what the label claims.

References

Peer-reviewed sources on Ipamorelin indexed in PubMed, listed for research context. Real Peptides supplies Ipamorelin for laboratory research use only.

The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior, 2024. PMID 39043357. doi:10.1016/j.physbeh.2024.114644
The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science, 2024. PMID 38996787. doi:10.1016/j.anireprosci.2024.107550
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 2014. PMID 25331030. doi:10.1007/s00384-014-2030-8
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology, 2012. PMID 27186127. doi:10.2147/JEP.S35396
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics, 2009. PMID 19289567. doi:10.1124/jpet.108.149211
Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters, 2004. PMID 15665799
Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 2002. PMID 12168778. doi:10.14670/HH-17.707
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2001. PMID 11735244. doi:10.1054/ghir.2001.0239

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Ipamorelin peptide and Ipamorelin are the exact same compound — a synthetic pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and molecular weight 711.85 g/mol. The term ‘peptide’ is sometimes added for product labelling clarity, but there is no distinct formulation or molecular variant called ‘Ipamorelin Peptide’ separate from ‘Ipamorelin.’ Both names refer to the same selective growth hormone secretagogue used in research.

Ipamorelin peptide is a selective GHS-R1a receptor agonist, meaning it binds almost exclusively to growth hormone secretagogue receptors without activating cortisol-releasing (ACTH) or prolactin pathways. GHRP-2 and GHRP-6 bind to multiple receptor types, causing cortisol elevation 3–5× higher and significant prolactin release — effects absent with ipamorelin. This selectivity makes ipamorelin the preferred choice in research protocols isolating GH’s metabolic or anabolic effects without secondary endocrine interference.

Lyophilised ipamorelin peptide should be stored at −20°C before reconstitution. Once mixed with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days — temperature excursions above 8°C accelerate oxidative degradation at methionine residues, reducing potency without visible changes to the solution. Any exposure to room temperature beyond 48 hours significantly compromises peptide integrity.

No — ipamorelin peptide and CJC-1295 should never be mixed in the same vial before use. Each compound has distinct stability profiles in solution, and co-mixing increases the risk of pH-driven degradation, peptide aggregation, and cross-contamination. Reconstitute each separately with bacteriostatic water, then draw both into the same syringe immediately before injection if simultaneous administration is required.

Ipamorelin peptide produces minimal to no cortisol or prolactin elevation in human trials, unlike GHRP-2 and GHRP-6 which significantly activate ACTH and lactotroph pathways. Comparative receptor binding assays show ipamorelin has 100-fold lower affinity for cortisol-releasing pathways, making it the cleanest option for GH research protocols where secondary endocrine activation would confound results.

Ipamorelin peptide has a circulating half-life of approximately two hours in both rodent models and human subjects based on Phase II pharmacokinetic data. This short half-life requires dosing 2–3 times daily in research protocols to sustain pulsatile GH output — unlike CJC-1295 (with DAC modification), which has a 6–8 day half-life and requires only weekly administration.

Ipamorelin peptide stimulates endogenous GH release from the pituitary via GHS-R1a receptor activation, maintaining physiological pulsatile secretion patterns and responsiveness to somatostatin regulation. Synthetic recombinant GH bypasses the pituitary entirely, delivering exogenous GH that suppresses endogenous production and eliminates natural pulsatility. Ipamorelin preserves regulatory feedback loops; recombinant GH overrides them.

Research-grade ipamorelin peptide should meet ≥98% purity as verified by HPLC and mass spectrometry analysis. Batches below 95% purity contain significant contaminant byproducts from incomplete synthesis or degradation, which introduce experimental variability and compromise reproducibility. Reputable suppliers provide batch-specific certificates of analysis (COAs) confirming purity, endotoxin levels, and amino acid sequencing fidelity.

Ipamorelin peptide initiates pulsatile GH release, while CJC-1295 (a GHRH analogue) amplifies the magnitude of each pulse. This mechanistic synergy produces GH elevations 2.5–3× higher than either compound alone, as demonstrated in comparative endocrinology studies. Ipamorelin provides the pulse frequency; CJC-1295 provides the pulse amplitude — combined use leverages both mechanisms for maximal GH output.

No — ipamorelin peptide does not significantly stimulate appetite, unlike GHRP-6 which activates ghrelin’s hunger-signalling pathways. Ipamorelin lacks the octanoyl modification required for full ghrelin receptor activation, allowing it to trigger GH release without the appetite surge. This makes ipamorelin the preferred choice in metabolic or body composition studies where appetite stimulation would confound results.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA